Other drugs on the list include Pfizer’s cancer drugs Ibrance and Xtandi, GSK’s asthma and chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta, Teva’s Huntington’s ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

Last year was a big year for Fairbanks Museum, highlighted by major moments in the museum’s 136-year history, but in 2025, the museum will focus on the smaller things, both literally and ...

SAN FRAN­CIS­CO — Ben Aus­pitz, a vet­er­an biotech in­vestor and re­peat en­tre­pre­neur, is re­unit­ing with long­time col­lab­o­ra­tor Alex­is Borisy and his “free the ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

GSK Plc ’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in 2024 ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...